Edition:
United States

ALK-Abello A/S (ALKb.CO)

ALKb.CO on Copenhagen Stock Exchange

1,065.00DKK
28 Apr 2017
Change (% chg)

kr.7.00 (+0.66%)
Prev Close
kr.1,058.00
Open
kr.1,058.00
Day's High
kr.1,065.00
Day's Low
kr.1,048.00
Volume
8,856
Avg. Vol
11,832
52-wk High
kr.1,300.00
52-wk Low
kr.839.00

ALKb.CO

Chart for ALKb.CO

About

ALK-Abello A/S is a Denmark-based company active within the pharmaceutical industry. It is engaged in the development and marketing of pharmaceutical products for the treatment, prevention and diagnosis of allergy. Its product portfolio comprises allergy vaccines, emergency treatments and allergy diagnostics products. The... (more)

Overall

Beta: 0.74
Market Cap(Mil.): kr.9,806.09
Shares Outstanding(Mil.): 9.21
Dividend: 5.00
Yield (%): 0.47

Financials

  ALKb.CO Industry Sector
P/E (TTM): 40.05 29.08 30.08
EPS (TTM): 26.59 -- --
ROI: 7.37 13.73 13.25
ROE: 9.69 14.68 14.41

BRIEF-ALK-Abello: Torii submits paediatric registration application for house dust mite SLIT-tablet in Japan

* ALK’s partner, Torii, submits paediatric registration application for the house dust mite SLIT-tablet in Japan

Mar 24 2017

BRIEF-ALK-Abello: FDA approval for HDM sublingual allergy immunotherapy tablet

* Said on Wednesday FDA approved Biologics License Application (BLA) for ALK's house dust mite (HDM) sublingual allergy immunotherapy (SLIT) tablet (ACARIZAX in Europe)

Mar 02 2017

BRIEF-Alk submits registration application for ragweed SLIT-tablet in Europe

* Alk submits registration application for ragweed SLIT-tablet in Europe

Feb 16 2017

BRIEF-Alk Abello Q4 EBITDA ex-items slightly down at DKK 121 million

* Q4 total revenue 754 million Danish crowns ($108.49 million) versus 687 million crowns year ago

Feb 07 2017

BRIEF-Alk Abello Q3 EBIT ex-items down at DKK 80 million, upgrades guidance

* Q3 total revenue 630 million Danish crowns ($93 million)versus 667 million crowns year ago

Nov 10 2016

More From Around the Web

Earnings vs. Estimates